Home > Oncology > ESMO 2021 > Breast Cancer > Longest survival benefit from first-line CDK4/6 inhibitor

Longest survival benefit from first-line CDK4/6 inhibitor

Presented By
Prof. Gabriel Hortobagyi, University of Texas MD Anderson Cancer Center, USA
Conference
ESMO 2021
Trial
Phase 3, MONALEESA-2
CDK4/6 inhibitor ribociclib added to endocrine therapy extended overall survival (OS) in treatment-naïve postmenopausal patients with HR-positive, HER2-negative, advanced, metastatic breast cancer. Data from the MONALEESA-2 trial showed that after a median follow-up of >6.5 years, median OS was 12 months longer for first-line ribociclib plus letrozole versus placebo plus letrozole. Prof. Gabriel Hortobagyi (University of Texas MD Anderson Cancer Center, USA) presented the late-breaking results highlighting the final OS analysis of the phase 3 MONALEESA-2 study (NCT01958021), which evaluated ribociclib (oral, 600 mg daily, 3 weeks on/1 week off) plus the aromatase inhibitor letrozole (oral, 2.5 mg daily), compared with placebo plus letrozole [1]. The primary endpoint of MONALEESA-2 (n=668) was met and reported previously, showing that ribociclib ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on